Cancer vaccine development: Protein transfer of membrane-anchored cytokines and immunostimulatory molecules

Immunologic Research

Volumn 29, Issue 1-3, 2004, Pages 231-240

  Cimino, Ashley M ^a   Palaniswami, Purani ^a   Kim, Andrew C ^a   Selvaraj, Periasamy ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CD80; Costimulation; Cytokines; GPI; IL 12; IL 2

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CD40 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INOSITOL DERIVATIVE; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; RECOMBINANT CYTOKINE; TOXIC SHOCK SYNDROME TOXIN 1;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ARTICLE; CELL ISOLATION; CELL MEMBRANE; CYTOKINE PRODUCTION; DENDRITIC CELL; DOWN REGULATION; DRUG RESEARCH; GENE TRANSFER; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; TUMOR; TUMOR CELL; TUMOR REGRESSION; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN-PRESENTING CELLS; CANCER VACCINES; CELL MEMBRANE; CYTOKINES; GENE THERAPY; GLYCOSYLPHOSPHATIDYLINOSITOLS; HUMANS; LYMPHOCYTE ACTIVATION; MICE; PROTEIN TRANSPORT; T-LYMPHOCYTES;

EID: 3042658654     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:29:1-3:231     Document Type: Article

References (89)

1. Mayordomo JI, Zorina T, Storkus WJ, et al.: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995;1:1297-1302.
2. Kawashima I, Tsai V, Southwood S, Takesako K, Sette A: Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Cancer Res 1999;59: 431-435.
3. Tjandrawan T, Martin DM, Maeurer MJ, Castelli C, Lotze MT: Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro. J Immunother 1998;21:149-157.
4. Nestle FO, Alijagic S, Gilliet M, et al.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-332.
5. Alexander RB, Brady F, Leffell MS, Tsai V, Celis E: Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer. Urology 1998;51:150-157.
6. Celis E, Fikes J, Wentworth P, et al.: Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles. Mol Immunol 1994;31:1423-1430.
7. Tuting T, Gambotto A, DeLeo A, Lotze MT, Robbins PD: Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Cancer Gene Ther 1999;6:73-80.
8. Tuting T, Gambotto A, DeLeo A, Lotze MT, Robbins PD, Storkus WJ: Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Cancer Gene Ther 1999;6:73-80.
9. Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL: Heat shock proteins come of age: primitive functions acquire new roles in adaptive world. Immunity 1998;8:657-665.
10. Yamazaki K, Nguyen T, Podack ER: Tumor secreted heat shock-fusion protein elicits CD8 cells for rejection. J Immunol 1999;163:5178-5182.
11. Guo Y, Wu M, Chen H, et al.: Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science 1994;263:518-520.
12. Townsend SE, Su FW, Atherton JM, Allison JP: Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res 1994; 54:6477-6483.
13. Pulaski BA, Ostrand-Rosenberg S: Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 1998;58:1486-1493.
14. Tahara H, Zitvogel L, Storkus WJ, et al.: Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1995;154:6466-6474.
15. Levitsky HI, Montgomery J, Ahmadzadeh M, et al.: Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 1996;156:3858-3865.
16. Zitvogel L, Robbins PD, Storkus WJ, et al.: Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol 1996;26:1335-1341.
17. McHugh RS, Nagarajan S, Wang YC, Sell KW, Selvaraj P: Protein transfer of glycosylphosphatidylinositol-B7-1 into tumor cell membranes: a novel approach to tumor immunotherapy. Cancer Res 1999;59:2433-2437.
18. Poloso N, Nagarajan S, Bumgarner GW, Selvaraj P: Development of therapeutic vaccines by direct modification of cell membranes from surgically removed human tumor tissue with immunostimulatory molecules. Vaccine 2001;19:2029-2038.
19. Nagarajan S, Selvaraj P: Glycolipid-anchored IL-12 expressed on tumor cell surface induces antitumor immune response. Cancer Res 2002;62:2869-2874.
20. Pardoll DM: Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995;13:399-415.
21. Trinchieri G: Biological properties and therapeutic applications of interleukin 12. Eur Cyto Netw 1997; 8:305-307.
22. Mach N, Dranoff G: Cytokine-secreting tumor cell vaccines. Curr Opin Immunol 2000;12:571-575.
23. Rosenberg SA: Lymphokine-activated killer cells: anew approach to immunotherapy of cancer. J Natl Cancer Inst 1985;75:595-603.
24. Tepper RI, Pattengale PK, Leder P: Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989;57:503-512.
25. Brunda MJ, Luistro L, Warrier RR, et al.: Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J Exp Med 1993;178:1223-1230.
26. Nastala CL, Edington HD, McKinney TG, et al.: Recombinant IL-12 administration induced tumor regression in association with IFN-gamma production. J Immunol 1994;153:1697-1706.
27. Dranoff G, Jaffee E, Lazenby A, et al.: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-3543.
28. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H: The central role of CD4+ T cells in the antitumor immune response. J Exp Med 1998; 188:2357-2368.
29. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348-2357.
30. McAdam AJ, Pulaski BA, Storozynsky E, et al.: Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocyte-monocyte colony-stimulating factor, and interferon-γ) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumor. Cell Immunol 1995;165:183-192.
31. Trinchieri G: Biology of natural killer cells. Adv Immunol 1989;47:187-303.
32. Baccarini M, Schwinzer R, Lohmann-Matthes ML: Effect of human recombinant IL-2 on murine macrophage precursors. Involvement of a receptor distinct from the p55 (Tac) protein. J Immunol 1989;142: 118-125.
33. Trinchieri G, Scott P: Interleukin-12: basic principles and clinical applications. Curr Top Microbiol Immunol 1999;238:57-78.
34. Rosenberg SA, Lotze MT, Mule JJ: New approaches to the immunotherapy of cancer using interleukin-2. Ann Intern Med 1988;108:853.
35. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA: High-dose recombinant interleukin 2 in treatment of patients with disseminated cancer. J Am Med Assoc 1986;526:3117-3124.
36. Rosenberg SA, Packard BS, Aebersold PM, Solomon D: Use of tumor-infiltrating lymphocytes and interlekin-2 in the immunotherapy of patients with metastatic melanoma. N Eng J Med 1988;319:1676.
37. Lotze MT, Matory YL, Ettinghausen SE, et al.: In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 1985;135:2865-2875.
38. Siegel JP, Puri RK: Interleukin-2 toxicity. J Clin Oncol 1991;9:694-704.
39. Leonard JP, Sherman ML, Fisher GL, et al.: Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997;90:2541-2548.
40. Mule JJ, Shu S, Schwartz SL, Rosenberg SA: Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 1984;225:1487-1489.
41. Yang JC, Rosenberg SA: Current approaches to the adoptive immunotherapy of cancer. Adv Exp Med Biol 1988;233:459-467.
42. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al.: Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol 1999; 163:1690-1695.
43. Mukherji B, Macalister TJ: Clonal analysis of cytotoxic T cell response against human melanomas. J Exp Med 1983;158:240.
44. Wang J, Saffold S, Cao X, Krauss J, Chen W: Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 1998;161:5516-5524.
45. Bhardwaj N: Processing and presentation of antigens by dendritic cells: implications for vaccines. Trends Mol Med 2001;7:388-394.
46. Fonteneau JF, Larsson M, Bhardwaj N: Dendritic cell-dead cell interactions: implications and relevance for immunotherapy. J Immunother 2001;24:294-304.
47. Dhodapkar MV, Bhardwaj N. Active immunization with dendritic cells. J Clin Immunol 2000;20:167-174.
48. Dhodapkar MV, Steinman RM, Sapp M, et al.: Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 1999;104:173-180.
49. Banchereau J, Palucka AK, Dhodapkar MV, et al.: Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res 2001;61:6451-6468.
50. Mueller DL, Jenkins MK, Schwartz RH: Clonal expansion versus functional clonal inactivation: A costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 1989;7:445-480.
51. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA: Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991; 173:721-730.
52. Azuma M, Cayabyab M, Buck D, Phillips JH, Lanier LL: CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes. J Exp Med 1992;175:353-360.
53. Gimmi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM: Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 1993;90:6586-6590.
54. Townsend SE, Allison JP: Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993;259:368-370.
55. Baskar S, Ostrand Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH: Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci USA 1993;90:5687-5690.
56. Tan P, Anasetti C, Hansen JA, et al.: Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993;177:165-173.
57. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP: CD28 mediated signalling costimulate murine T cells and prevents induction of anergy in T cell clones. Nature 1992;356:607.
58. Porgador A, Gansbacher B, Bannerji R, et al.: Anti-metastatic vaccination of tumor-bearing mice with IL-2-gene- inserted tumor cells. Int J Cancer 1993;53: 471-477.
59. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E: IL-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990;172:1217-1224.
60. Fearon ER, Pardoll DM, Itaya T, et al.: Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990;60: 397-413.
61. Li Y, McGowan P, Hellstrom I, Hellstrom KE, Chen L: Costimulation of tumor reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol 1994;153:421-428.
62. Baskar S, Glimcher L, Nabavi N, Jones R, Ostrand-Rosenburg S: Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 1995;181:619-629.
63. Wang Y-C, Zhu L, McHugh R, et al.: Induction of autologous tumor-specific cytotoxic T-lymphocyte activity against a human renal carcinoma cell line by B7-1 (CD80) costimulation. J Immunother 1996;19:1-8.
64. Nabel EG, Plautz G, Nabel GJ: Transduction of a foreign histocompatibility gene into the arterial wall induces vasculitis. Med Sci 1992;89:5157-5161.
65. Ada GL: Vaccines. In Fundamental Immunology, 768th ed. (Paul WE, ed). Raven Press, New York, 1993; pp. 1309-1352.
66. Davis HL, Demeneix BA, Quantin B, Coulombe J, Whalen RG: Plasmid DNA is superior to viral vectors for direct gene transfer into adult mouse skeletal muscle. Hum Gene Ther 1993;4:733-740.
67. Simons JW, Jaffee EM, Weber CE, et al.: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Hum Gene Ther 1997; 57:1537-1546.
68. McHugh RS, Ahmed SN, Wang Y-C, Sell KW, Selvaraj P: Construction, purification and functional reconstitution on tumor cells of glycolipid-anchored human B7-1 (CD80). Proc Natl Acad Sci USA 1995;92: 8059-8063.
69. Brunschwig EB, Levine E, Trefzer U, Tykocinski ML: Glycosylphosphatidylinositol-modified murine B7-1 and B7-2 retain costimulator function. J Immunol 1995;155:5498-5505.
70. Selvaraj P, McHugh RS, Nagarajan S: Engineering GPI-anchored proteins. In MBIU 7: GPI-Anchored Membrane Proteins and Carbohydrates. (Hoessli D, Ilangumaran S, eds.). Landes Biosciences, Texas, 1999, pp. 197-211.
71. Nagarajan S, Selvaraj P: Reconstitution of CD16 expression on nucleated cells using purified CD16. FASEB J 1991;5:A1718.(Abstract)
72. Nagarajan S, Anderson M, Ahmed SN, Sell KW, Selvaraj P: Purification and optimization of functional reconstitution on the surface of leukemic cell lines of GPI-anchored Fcγ receptor III. J Immunol Methods 1995;184:241-251.
73. Medof ME, Kinoshita T, Nussenzweig V: Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 1984;160:1558-1563.
74. Zhang F, Schmidt WG, Hou Y, Williams AF, Jacobson K: Spontaneous incorporation of the glycosyl-phosphatidylinositol-linked protein Thy-1 into cell membranes. Proc Natl Acad Sci USA 1992;89:5231-5235.
75. Huang JH, Greenspan NS, Tykocinski ML: Alloantigenic recognition of artificial glycosyl phosphatidylinositol-anchored HLA-A2.1. Mol Immunol 1994;31: 1017-1028.
76. Diamond DC, Finberg R, Chaudhuri S, Sleckman BP, Burakoff SJ: Human immunodeficiency virus infection is efficiently mediated by a glycolipid-anchored form of CD4. Proc Natl Acad Sci USA 1990;87:5001-5005.
77. Jasin M, Page KA, Littman DR: Glycosylphosphatidylinositol-anchored CD4/Thy-1 chimeric molecules serve as human immunodeficiency virus receptors in human, but not mouse, cells and are modulated by gangliosides. J Virol 1991;65:440-444.
78. Ferguson MAJ, Williams AF: Cell surface anchoring of proteins via glycosyl-phosphatidylinositol structures. Annu Rev Biochem 1988;57:285-320.
79. Low MG, Saltiel AR: Structural and functional roles of phosphatidylinositol in membranes. Science 1988;239: 268-275.
80. van Broekhoven CL, Parish CR, Vassilou G, Altin JG: Engrafting costimulatory molecules onto tumor cell surfaces with chelator lipids: a potentially convenient approach in cancer vaccine development. J Immunol 2000;164:2433-2443.
81. Wahlsten JL, Mills CD, Ramakrishnan S: Antitumor response elicited by a superantigen-transmembrane sequence fusion protein anchored onto tumor cells. J Immunol 1998;161:6761-6767.
82. Chen L, McGowan P, Ashe S, Johnston J, Hellstrom I, Hellstrom K: B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with corynebacterium parvum. Cancer Res 1994;54:5420-5423.
83. Pardoll DM, Topalian SL: The role of CD4+ T cell responses in antitumor immunity. [Review] [49 refs]. Curr Opin Immunol 1998;10:588-594.
84. Billadeau DD: ITAMs versus ITIMs: striking a balance during cell regulation. J Clin Invest 2002;109:161-168.
85. Poloso NJ, Nagarajan S, Mejia-Oneta JM, Selvaraj P: GPI-anchoring of GM-CSF results in active membrane-bound and partially shed cytokine. Mol Immunol 2002;38:803-816.
86. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 1998;392:245-252.
87. Zampell JC, Palaniswami P, Nagarajan S, Poloso N, Selvaraj P: Interleukin-2 expressed as a cell surface molecule induces antitumor immune reponse in mice. FASEB J 2003 (Abstract).
88. Fukao T, Koyasu S: Expression of functional IL-2 receptors on mature splenic dendritic cells. Eur J Immunol 2000;30:1453-1457.
89. Verma UN, Mazumder A: Interleukin-12 (IL-12) alone or in synergistic combination with IL-2 for in vitro activation of human bone marrow: differential effects at different time points. Bone Marrow Transpl 1995; 16:365-372.